|
WO2021069571A1
|
|
Polymorph of lorlatinib
|
|
WO2021004895A1
|
|
Crystalline forms of an orally available, selective kit and pdgfr kinase inhibitor
|
|
WO2021001457A1
|
|
Crystalline (r)-2-amino-3-phenylpropylcarbamate acid addition salts
|
|
WO2020239759A1
|
|
Amorphous enasidenib in a stabilized form
|
|
WO2020208140A1
|
|
Rifaximin-containing granules
|
|
WO2020182978A1
|
|
Crystalline salt of a 5-ht2a receptor antagonist
|
|
WO2020187674A1
|
|
Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate
|
|
WO2020161284A1
|
|
Crystalline form of iclaprim mesylate
|
|
WO2020127887A1
|
|
Process for the preparation of an intermediate product of ivosidenib
|
|
WO2020099483A1
|
|
Crystalline forms of brigatinib
|
|
WO2020108941A1
|
|
Multi-component crystals of an orally available hif prolyl hydroxylase inhibitor
|
|
EP3812007A1
|
|
New formulations of fosfomycin with reduced sodium content for parenteral use and methods of producing the same
|
|
CA3113770A1
|
|
Co-crystals comprising levothyroxine and a dicarboxylic acid
|
|
EP3808742A1
|
|
Polymorph of selinexor
|
|
WO2020043763A1
|
|
Process for preparing elagolix formulations and dosage forms comprising the same
|
|
WO2020020999A1
|
|
Process for preparing rapidly or very rapidly dissolving tablets comprising freely soluble api
|
|
US2021087175A1
|
|
Crystalline Form II of Darolutamide
|
|
EP3693364A1
|
|
Crystalline salts of a hemoglobin s allosteric modulator
|
|
WO2019158421A1
|
|
Pharmaceutical composition of brigatinib
|
|
CN111699190A
|
|
Crystalline forms of bicalutavir sodium
|
